ADC Therapeutics (ADCT) Non-Current Debt (2020 - 2026)

ADC Therapeutics has disclosed Non-Current Debt across 7 years of filings, most recently posting $110.4 million for Q2 2026.

• In Q2 2026, Non-Current Debt fell 3.55% year-over-year to $110.4 million; the TTM figure through Jun 2026 stood at $110.4 million (down 3.55% YoY), while the FY2025 annual figure was $112.5 million, down 1.04% from the prior year.
• Non-Current Debt came in at $110.4 million for Q2 2026 at ADC Therapeutics, down from $111.0 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $115.2 million in Q3 2025 to a low of $88.4 million in Q1 2022.
• Average Non-Current Debt over 5 years is $106.8 million, with a median of $111.7 million recorded in 2025.
• Year-over-year, Non-Current Debt jumped 147.16% in 2022 and retreated 3.55% in 2026.
• Over 5 years, Non-Current Debt stood at $109.7 million in 2022, then gained by 2.75% to $112.7 million in 2023, then climbed by 0.8% to $113.6 million in 2024, then slipped by 1.04% to $112.5 million in 2025, then fell by 1.79% to $110.4 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $110.4 million in Q2 2026, $111.0 million in Q1 2026, and $112.5 million in Q4 2025.